PAS-004 (MEK Inhibitor)

About Pasithea Therapeutics

Pasithea Therapeutics is a micro-cap biotech founded in 2020 with a mission to develop innovative treatments for CNS disorders and RASopathies. Its core strategy is the targeted application of MEK inhibitors, based on the scientific rationale that dysregulation of the RAS/MAPK pathway is a key driver in conditions like NF1, ALS, and MS. The company has assembled a leadership team with deep neuroscience and drug development expertise, led by renowned neurologist and immunologist Professor Lawrence Steinman. While still in the early stages of development with a preclinical/IND-enabling pipeline, Pasithea is targeting large, underserved markets with a mechanism-driven approach.

Therapeutic Areas

Other Neurofibromatosis Type 1 (NF1) Drugs